Introduction
Hypercalcaemia accompanying sarcoidosis is due to a rise in circulating active vitamin D metabolite, 1,25-dihydroxycholecalciferol (1,25-DHCC). Moreover, corticosteroid administration produces a simultaneous decline in serum calcium and 1,25-DHCC concentrations (Bell et al., 1979; Zerwekh et al., 1980) . In these studies, serum immunoreactive parathyroid hormone (PTH) concentration was suppressed to very low levels in the presence of hypercalcaemia. Serum PTH concentration is generally low in sarcoidosis, but may be elevated when there is co-existent primary hyperparathyroidism (Cushard et al., 1972) . In hypercalcaemia arising from primary hyperparathyroidism, the serum PTH level may remain within the normal range, particularly when there is no evidence of skeletal involvement (Addison et al., 1971 (Taylor, Lynch and Wysor, 1963 The association of sarcoidosis with primary hyperparathyroidism is well known (Dent and Watson, 1966; Winnacker et al., 1969) , and a recent report revealed that 23 cases have been described (Robinson, Kerwin and Tsou, 1980) . In a patient with biopsy-proven sarcoidosis and hypercalcaemia, in whom bone X-rays fail to demonstrate periosteal reabsorption, the serum PTH level, and the response to corticosteroid administration (Anderson et al., 1954) , and primary hyperparathyroidism (Broadus et al., 1980) , ranging from 40-140 pg/ml. In the present case, corticosteroids reduced serum 1,25-DHCC from
